Vivos Therapeutics GAAP EPS of -$0.52 misses by $0.07, revenue of $5.14M beats by $0.79M
Source: SeekingAlpha
2026-05-20 16:29:25 ET
More on Vivos Therapeutics
- Vivos Therapeutics, Inc. (VVOS) Q4 2025 Earnings Call Transcript
- Vivos targets cash flow positive operations by end of 2026 as it scales SO teams with $500,000+ monthly collections potential
- Seeking Alpha’s Quant Rating on Vivos Therapeutics
- Historical earnings data for Vivos Therapeutics
- Financial information for Vivos Therapeutics
Read the full article on Seeking Alpha
For further details see:
Vivos Therapeutics GAAP EPS of -$0.52 misses by $0.07, revenue of $5.14M beats by $0.79M
Vivos Therapeutics Inc.
NASDAQ: VVOS
VVOS Trading
67.94% G/L:
$1.125 Last:
54,524,518 Volume:
$0.7251 Open:
VVOS Latest News
June 05, 2026 08:45:00 am
Vivos Therapeutics Announces Binding Agreement for Senior Debt-to-Equity Exchange of Up to $4.5 Million from Streeterville Capital to Support Continued Nasdaq Listing
May 20, 2026 04:10:00 pm
Vivos Therapeutics Reports First Quarter 2026 Financial Results and Provides Operational Update
VVOS Stock Data
$16,280,184
8,040,995
N/A
7
N/A
Medical Equipment & Supplies
Healthcare
US
Littleton
